Shaker Investments LLC OH Invests $550,000 in Omnicell, Inc. (NASDAQ:OMCL)

Shaker Investments LLC OH purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,357 shares of the company's stock, valued at approximately $550,000.

Other large investors also recently made changes to their positions in the company. Victory Capital Management Inc. increased its stake in Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company's stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. purchased a new position in Omnicell in the third quarter valued at about $32,721,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Omnicell by 750.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company's stock worth $12,820,000 after buying an additional 259,463 shares during the period. ArrowMark Colorado Holdings LLC lifted its position in Omnicell by 27.1% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock worth $49,742,000 after acquiring an additional 243,353 shares in the last quarter. Finally, Pier Capital LLC purchased a new position in Omnicell in the 3rd quarter valued at about $5,859,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.64% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. Craig Hallum raised their price target on Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Benchmark reiterated a "buy" rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of "Hold" and an average target price of $52.33.

Omnicell Trading Down 1.6 %

Shares of OMCL stock traded down $0.64 during trading hours on Friday, reaching $39.58. 118,297 shares of the stock traded hands, compared to its average volume of 398,946. The business has a fifty day moving average price of $43.77 and a 200 day moving average price of $43.61. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a quick ratio of 0.95, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.83 billion, a PE ratio of 146.80, a PEG ratio of 26.98 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, equities research analysts forecast that Omnicell, Inc. will post 1.04 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.